Mesalazine
- Generic Name
- Mesalazine
- Brand Names
- Apriso, Asacol, Canasa, Delzicol, Lialda, Mezavant, Pentasa, Rowasa, Salofalk, Zaldyon
- Drug Type
- Small Molecule
- Chemical Formula
- C7H7NO3
- CAS Number
- 89-57-6
- Unique Ingredient Identifier
- 4Q81I59GXC
Overview
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent . Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules . In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.
Background
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent . Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules . In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.
Indication
适用于溃疡性结肠炎和克罗恩病（Crohn病）。
Associated Conditions
- Acute Ulcerative Colitis
- Crohn's Disease Relapse
- Crohn's Ileocolitis
- Mild to Moderate Ulcerative Colitis
- Proctitis
- Proctitis, Ulcerative
- Proctosigmoiditis
- Ulcerative Colitis in Remission
- Mild Ulcerative Colitis
- Mild to moderate distal ulcerative colitis
- Moderate Ulcerative colitis
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.